Technimark acquires Rage
Technimark has acquired Rage Custom Plastics, a US-based manufacturer known for its blow moulding capabilities. This acquisition, for an undisclosed amount, is designed to enhance Technimark's presence in the high-growth healthcare sector and expand its domestic manufacturing footprint in the Midwest and Mid-Atlantic regions of the United States. It also adds significant value-added blow moulding capabilities to Technimark's portfolio.
Rage Custom Plastics, established 65 years ago, is acknowledged for its emphasis on manufacturing excellence and customer service. As a family-run business, it has built a reputation for prioritizing quality and communication. According to Dan Saliaris, CEO of Rage, the partnership with Technimark aligns well with the values and culture instilled by his father who founded the company. Saliaris expressed confidence that the acquisition would strengthen Rage's legacy while creating new opportunities for both employees and customers.
The acquisition is a strategic move for Technimark, which seeks to leverage Rage's strong culture and its long-term partnerships with strategic healthcare customers. Kris Peavy, Technimark’s Chief Commercial Officer and President of Healthcare, highlighted Rage's talented team and robust customer relationships as key factors making the acquisition a perfect fit. The integration of Rage is expected to bolster Technimark’s mission to deliver products that improve quality of life.
In a competitive healthcare market, this acquisition underscores the trend of consolidation as companies aim to expand capabilities and geographic reach. Technimark's bolstering of its domestic operations comes as industry players continue to seek efficiencies and broader service offerings to meet market demands. The move positions Technimark more competitively against rivals who are also pursuing growth through acquisitions and technological advancements.
Looking ahead, Technimark will focus on integrating Rage's operations, capitalizing on enhanced product offerings, and potentially exploring further strategic acquisitions to augment its market presence. The transaction's completion will be subject to the usual regulatory approvals, although no specific hurdles are anticipated given the standard nature of this type of acquisition in the sector.
Deal timeline
This transaction is classified in Healthcare. Figures and status may change as sources update.